Cereno Scientific's drug candidate CS585 published in top-tier journal Blood with favorable preclinical data on prevention of thrombosis
Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a publication concerning drug candidate CS585 has been published in the top peer-reviewed medical journal Blood. The publication shows that CS585, a prostacyclin receptor agonist, is a highly potent and selective compound given both orally and intravenously and prevents thrombosis for up to 48 hours as observed in preclinical studies.
The publication titled "The oxylipin analogue CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor", was authored by L. Stanger et al.
"This is the first paper that shows that a prostacyclin receptor agonist can elicit sustained inhibition of platelet activity in the blood for days; the effect of CS585 was observed for up to 48 hours. In comparison, some FDA-approved prostacyclin receptor agonists (PRA) drugs such as iloprost, are recommended to be given 6-9 times per day for the treatment of PAH. Therefore, CS585 could be a game-changer for patients based on its sustained protection without the increased risk for bleeding," said Michael Holinstat, lead of Cereno's development programs at the University of Michigan and Director of Translational Research at Cereno. "In this paper, we observed that animals treated with CS585 had a significant reduction of thrombus size than those not treated following vessel injury. I am very excited by the findings of this paper and the potential of CS585 as a treatment in the prevention of thrombosis."
"I am very pleased to see our promising drug candidate CS585 recognized in a prestigious journal such as Blood. Publication in peer-reviewed journals is an important activity in Cereno's strategy to continue to establish our presence and reputation in the scientific community," said Sten R. Sörensen, CEO, Cereno Scientific.
The medical journal Blood is published by the American Society of Hematology. Bloodis the most cited peer-reviewed publication in the field of hematology. It provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology.
Access the publication: Livia Stanger,Adriana Yamaguchi,Pooja Yalavarthi,Sylviane Lambert,Devin Gilmore,Andrew Rickenberg,Catherine Luke,Kiran Kumar,Andrea T Obi,Andrew White,Niklas Bergh,Bjorn Lennart Dahlof,Michael Holinstat; The oxylipin analogue CS585 prevents platelet activation and thrombosis through activation of the prostacyclin receptor.Blood2023; blood.2023020622. doi:https://doi.org/10.1182/blood.2023020622
For further information, please contact:
About Cereno Scientific AB
Cereno Scientific is a clinical-stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH). CS1 is an HDAC (histone deacetylase) inhibitor that acts as an epigenetic modulator with pressure-reducing, reverse-remodeling, anti-inflammatory, anti-fibrotic and anti-thrombotic properties, all relevant for PAH. A clinical Phase II study is ongoing to evaluate CS1's safety, tolerability, and efficacy in patients with PAH. A collaboration agreement with global healthcare company Abbott allows Cereno to use their cutting-edge technology CardioMEMS HF System in the study. Cereno also has two promising preclinical drug candidates in development for cardiovascular disease through research collaborations with the University of Michigan. Drug candidate CS014 is a novel HDAC inhibitor with epigenetic effects, selected for prevention of thrombosis as target indication. In preclinical studies it has been documented to regulate platelet activity, ﬁbrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding. Thrombosis prevention in venous or arterial and cardiovascular disease has been selected as the first indication area for CS014. Drug candidate CS585 is a prostacyclin receptor agonist that has been documented in preclinical studies to target the IP receptor for prevention of thrombosis without increased risk of bleeding. The company is headquartered in Gothenburg, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Nasdaq First North (CRNO B). More information on www.cerenoscientific.com.